Previous 10 | Next 10 |
Shares of Compugen (NASDAQ: CGEN) rose 17.86% on Thursday. The clinical-stage immunotherapy pharmaceutical company focuses on oncology therapies and uses artificial intelligence to find new drug targets and biological pathways for cancer therapies. The stock closed on Wednesday ...
Are Penny Stocks A Buy Under $1 Or Too Risky? According to the definition of penny stocks, we’re discussing stocks under $5 per share. However, if you’re reading this article looking to make quick money, chances are you’re thinking something along the line of stocks...
Israel's Compugen ( NASDAQ: CGEN ) said it expects to receive a milestone payment of $7.5M from AstraZeneca as the British drugmaker dosed the first patient in its phase 2 trial of anti-tumor drug AZD2936. The phase 2 study, dubbed ARTEMIDE, is evaluating ...
Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT Bispecific PR Newswire Advancement of AZD2936, a PD-1/TIGIT bispecific antibody derived from COM902, into Phase 2, triggers $7.5 million milestone payment from AstraZe...
The following slide deck was published by Compugen Ltd. in conjunction with their 2022 Q3 earnings call. For further details see: Compugen Ltd. 2022 Q3 - Results - Earnings Call Presentation
Compugen Ltd. (CGEN) Q3 2022 Earnings Conference Call November 14, 2022 08:30 ET Company Participants Yvonne Naughton - Head, Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Henry Adewoye - Chief Medical Of...
Stocks in the ever-volatile biotech sector have many ups and downs, and Monday wasn't one of the ups for Compugen (NASDAQ: CGEN) . The cancer treatment developer published its latest set of quarterly results, and investors showed their displeasure by trading the company's shares dow...
Compugen press release ( NASDAQ: CGEN ): Q3 GAAP EPS of -$0.14 misses by $0.01 . As of September 30, 2022, cash, cash equivalents, short-term bank deposits and restricted cash totaled approximately $88 million, compared with approximately $118 million as of December 31...
Compugen Reports Third Quarter 2022 Results PR Newswire New encouraging preliminary clinical data, presented at SITC 2022, showing anti-tumor activity supported by potent immune activation in the tumor microenvironment following combination of COM701 and nivolumab in m...
Compugen ( NASDAQ: CGEN ) is scheduled to announce Q3 earnings results on Monday, November 14th, before market open. The consensus EPS Estimate is -$0.14 (-100.0% Y/Y) Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. For furth...
News, Short Squeeze, Breakout and More Instantly...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...